GC Pharma has won a bid to supply 2.63 million doses of the seasonal influenza vaccine for 2025-2026 to the Korea Disease Control and Prevention Agency (KDCA). The KDCA has adopted the trivalent influenza vaccine for its National Immunization Program, following World Health Organization (WHO) recommendations. The WHO declared the B/Yamagata lineage virus essentially extinct, leading to a global shift to trivalent flu vaccines, which experts say are as effective as quadrivalent vaccines.
Original Article: Read More
Auto-posted at: 2025-05-26 21:03:12